EQUITY RESEARCH MEMO

RS Medical

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)65/100

RS Medical is a US-based private medical device company specializing in prescription-grade electrotherapy devices for chronic pain management and muscle rehabilitation. Founded in 1990, the company's flagship product, the RS-4i Plus, utilizes patented Intersperse technology to combine Interferential Therapy (IFT) and Neuromuscular Electrical Stimulation (NMES). With over 1.5 million patients treated, RS Medical has established a strong foothold in the home-use electrotherapy market. The company's products are prescribed by healthcare providers for conditions such as chronic musculoskeletal pain, offering non-invasive, drug-free relief.

Upcoming Catalysts (preview)

  • Q4 2026FDA Clearance for Next-Generation RS-4i Device70% success
  • Q2 2027Expansion into International Markets (EU/Asia)50% success
  • Q3 2026Strategic Partnership for Distribution with Major Orthopedic Group60% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)